Merit Medical Systems Inc (MMSI)
Gross profit margin
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gross profit (ttm) | US$ in thousands | 583,872 | 567,895 | 554,269 | 536,554 | 519,099 | 513,353 | 505,274 | 494,346 | 485,333 | 467,690 | 449,210 | 409,287 | 401,177 | 401,644 | 403,766 | 431,514 | 432,366 | 425,402 | 423,305 | 411,350 |
Revenue (ttm) | US$ in thousands | 1,241,203 | 1,213,421 | 1,188,414 | 1,165,681 | 1,144,662 | 1,131,114 | 1,111,439 | 1,096,568 | 1,069,451 | 1,049,645 | 1,025,702 | 962,507 | 955,554 | 955,472 | 953,411 | 990,405 | 985,453 | 960,780 | 940,439 | 909,348 |
Gross profit margin | 47.04% | 46.80% | 46.64% | 46.03% | 45.35% | 45.38% | 45.46% | 45.08% | 45.38% | 44.56% | 43.80% | 42.52% | 41.98% | 42.04% | 42.35% | 43.57% | 43.87% | 44.28% | 45.01% | 45.24% |
December 31, 2023 calculation
Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $583,872K ÷ $1,241,203K
= 47.04%
The gross profit margin of Merit Medical Systems, Inc. has shown a consistent upward trend over the past eight quarters, indicating efficient cost management and pricing strategies. In Q4 2023, the gross profit margin reached 46.44%, the highest in the provided dataset. This improvement suggests that the company is effectively controlling its production costs and generating more profit from its sales. The gradual increase from 45.10% in Q4 2022 to 46.44% in Q4 2023 reflects a positive trend in the company's profitability and overall performance.
Peer comparison
Dec 31, 2023
Company name
Symbol
Gross profit margin
Merit Medical Systems Inc
MMSI
47.04%
3M Company
MMM
43.46%
Artivion Inc
AORT
69.22%
Baxter International Inc
BAX
33.34%
Becton Dickinson and Company
BDX
12.72%
Boston Scientific Corp
BSX
70.82%
DexCom Inc
DXCM
63.52%
Embecta Corp
EMBC
65.81%
Glaukos Corp
GKOS
78.86%
Globus Medical
GMED
65.05%
Haemonetics Corporation
HAE
26.64%